Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres-Reference-Cited by-同舟云学术

Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres

Published:2017-11-03 Issue:1 Volume:6 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Toellner Hannah¹^ORCID,Hughes G.²,Beswick W.³,Crooks M. G.³,Donaldson C.⁴,Forrest I.⁴,Hart S. P.³,Leonard C.²,Major M.³,Simpson A. J.⁴,Chaudhuri N.²

Affiliation:

1. Manchester Medical SchoolUniversity of ManchesterStopford Building, Oxford RdM13 9PTManchesterUK

2. Manchester University NHS Foundation TrustWythenshawe HospitalSouthmoor Rd, WythenshaweM23 9LTManchesterUK

3. Hull and East Yorkshire Hospitals NHS TrustCastle RoadHU16 5JQCottinghamUK

4. Newcastle Upon Tyne Hospitals NHS TrustQueen Victoria RdNE1 4LPNewcastle upon TyneUK

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1186/s40169-017-0172-3

Reference17 articles.

1. Classification and Natural History of the Idiopathic Interstitial Pneumonias

2. The diagnosis and treatment of idiopathic pulmonary fibrosis;Behr J;Dtsch Arztebl Int,2013

3. NICE guidelines.Idiopathic pulmonary fibrosis in adults: diagnosis and management.2013.https://www.nice.org.uk/guidance/cg163?unlid=26753404320163112522. Accessed 15 June 2016

4. Pathogenesis of Idiopathic Pulmonary Fibrosis

5. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan;Respiratory Investigation;2024-09

2. Safety, effectiveness, and usefulness of higher-dose tablets of generic pirfenidone in patients with IPF: a nationwide observational study in South Korea;Frontiers in Pharmacology;2024-08-09

3. Enhancing Outcomes in Chronic Fibrotic Interstitial Lung Disease Through Aggressive Management of Nintedanib-Induced Adverse Drug Reactions: A Retrospective Analysis;Drugs - Real World Outcomes;2024-08-05

4. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases;Medicine;2024-07-12

5. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04